BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 30039427)

  • 21. Ovarian malignant ascites-derived lymphocytes stimulated with prothymosin α or its immunoactive decapeptide lyse autologous tumour cells in vitro and retard tumour growth in SCID mice.
    Voutsas IF; Pistamaltzian N; Tsiatas ML; Skopeliti M; Katsila T; Mavrothalassiti I; Spyrou S; Dimopoulos MA; Tsitsilonis OE; Bamias A
    Eur J Cancer; 2013 May; 49(7):1706-14. PubMed ID: 23276721
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity.
    Santos JM; Heiniö C; Cervera-Carrascon V; Quixabeira DCA; Siurala M; Havunen R; Butzow R; Zafar S; de Gruijl T; Lassus H; Kanerva A; Hemminki A
    J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31940588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs).
    Nguyen LT; Yen PH; Nie J; Liadis N; Ghazarian D; Al-Habeeb A; Easson A; Leong W; Lipa J; McCready D; Reedijk M; Hogg D; Joshua AM; Quirt I; Messner H; Shaw P; Crump M; Sharon E; Ohashi PS
    PLoS One; 2010 Nov; 5(11):e13940. PubMed ID: 21085676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1
    Salas-Benito D; Conde E; Tamayo-Uria I; Mancheño U; Elizalde E; Garcia-Ros D; Aramendia JM; Muruzabal JC; Alcaide J; Guillen-Grima F; Minguez JA; Amores-Tirado J; Gonzalez-Martin A; Sarobe P; Lasarte JJ; Ponz-Sarvise M; De Andrea CE; Hervas-Stubbs S
    Br J Cancer; 2021 Mar; 124(6):1138-1149. PubMed ID: 33402737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro.
    Li Y; Liu S; Hernandez J; Vence L; Hwu P; Radvanyi L
    J Immunol; 2010 Jan; 184(1):452-65. PubMed ID: 19949105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization and comparison of 'standard' and 'young' tumour-infiltrating lymphocytes for adoptive cell therapy at a Danish translational research institution.
    Donia M; Junker N; Ellebaek E; Andersen MH; Straten PT; Svane IM
    Scand J Immunol; 2012 Feb; 75(2):157-67. PubMed ID: 21955245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy.
    Komdeur FL; Wouters MC; Workel HH; Tijans AM; Terwindt AL; Brunekreeft KL; Plat A; Klip HG; Eggink FA; Leffers N; Helfrich W; Samplonius DF; Bremer E; Wisman GB; Daemen T; Duiker EW; Hollema H; Nijman HW; de Bruyn M
    Oncotarget; 2016 Nov; 7(46):75130-75144. PubMed ID: 27650547
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor infiltrating lymphocytes in ovarian cancer.
    Santoiemma PP; Powell DJ
    Cancer Biol Ther; 2015; 16(6):807-20. PubMed ID: 25894333
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Solid-phase anti-CD3 antibody activation and cryopreservation of human tumor-infiltrating lymphocytes derived from epithelial ovarian cancer.
    Ikarashi H; Aoki Y; Fujita K; Kodama S; Tanaka K
    Jpn J Cancer Res; 1992 Dec; 83(12):1359-65. PubMed ID: 1483950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ex vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells.
    Nham T; Poznanski SM; Fan IY; Shenouda MM; Chew MV; Lee AJ; Vahedi F; Karimi Y; Butcher M; Lee DA; Hirte H; Ashkar AA
    Cancer Immunol Immunother; 2018 Apr; 67(4):575-587. PubMed ID: 29299659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunologic features of tumor-infiltrating lymphocytes and peripheral blood lymphocytes in ovarian cancer patients.
    Schöndorf T; Engel H; Kurbacher CM; Brenne U; Kolhagen H; Göhring UJ; Scharl A; Mallmann P
    J Soc Gynecol Investig; 1998; 5(2):102-7. PubMed ID: 9509389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation between class I antigen expression and the ability to generate tumour infiltrating lymphocytes from bladder tumour biopsies.
    Nouri AM; dos Santos AV; Crosby D; Oliver RT
    Br J Cancer; 1991 Dec; 64(6):996-1000. PubMed ID: 1764393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma-Implications for Adoptive Cell Therapy.
    Andersen R; Westergaard MCW; Kjeldsen JW; Müller A; Pedersen NW; Hadrup SR; Met Ö; Seliger B; Kromann-Andersen B; Hasselager T; Donia M; Svane IM
    Cancer Immunol Res; 2018 Feb; 6(2):222-235. PubMed ID: 29301752
    [No Abstract]   [Full Text] [Related]  

  • 34. Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer.
    Junker N; Andersen MH; Wenandy L; Dombernowsky SL; Kiss K; Sørensen CH; Therkildsen MH; Von Buchwald C; Andersen E; Straten PT; Svane IM
    Cytotherapy; 2011 Aug; 13(7):822-34. PubMed ID: 21428850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adoptive immunotherapy against ovarian cancer.
    Mittica G; Capellero S; Genta S; Cagnazzo C; Aglietta M; Sangiolo D; Valabrega G
    J Ovarian Res; 2016 May; 9(1):30. PubMed ID: 27188274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy.
    Liu S; Etto T; Rodríguez-Cruz T; Li Y; Wu C; Fulbright OJ; Hwu P; Radvanyi L; Lizée G
    J Immunother; 2010 May; 33(4):371-81. PubMed ID: 20386469
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TIL expansion with high dose IL-2 or low dose IL-2 with anti-CD3/anti-CD28 stimulation provides different quality of TIL-expanded T cell clones.
    Kongkaew T; Thaiwong R; Tudsamran S; Sae-Jung T; Sengprasert P; Vasuratna A; Suppipat K; Reantragoon R
    J Immunol Methods; 2022 Apr; 503():113229. PubMed ID: 35101548
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined Immunoscore of CD103 and CD3 Identifies Long-Term Survivors in High-Grade Serous Ovarian Cancer.
    Bösmüller HC; Wagner P; Peper JK; Schuster H; Pham DL; Greif K; Beschorner C; Rammensee HG; Stevanović S; Fend F; Staebler A
    Int J Gynecol Cancer; 2016 May; 26(4):671-9. PubMed ID: 26905331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Characteristics of Naive-like T Cells in Tumor-infiltrating Lymphocytes From Human Lung Cancer.
    Sheng SY; Gu Y; Lu CG; Tang YY; Zou JY; Zhang YQ; Wang RF; Hong H
    J Immunother; 2017 Jan; 40(1):1-10. PubMed ID: 27828929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CTLA-4 blockade boosts the expansion of tumor-reactive CD8
    Friese C; Harbst K; Borch TH; Westergaard MCW; Pedersen M; Kverneland A; Jönsson G; Donia M; Svane IM; Met Ö
    Sci Rep; 2020 Mar; 10(1):3914. PubMed ID: 32127601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.